Literature DB >> 7851213

A retrospective study of hepatitis C virus carriers in a local endemic town in Japan. A possible presence of asymptomatic carrier.

S Ohkoshi1, H Tawaraya, K Kuwana, T Harada, M Watanabe, S Higuchi, H Kojima, T Kamimura, H Asakura.   

Abstract

Chronic hepatitis, cirrhosis, and hepatocellular carcinoma are the accepted sequelae of chronic hepatitis C virus (HCV) infection. However, the real natural history of HCV infection is not still well understood. To approach this problem, we investigated 91 individuals positive for antibodies against HCV (anti-HCV), who have received annual liver function examination in a local town known to have had high carrier rates of hepatitis B virus (HBV) and HCV. Among the 91 anti-HCV-positive individuals, 63 had undertaken the annual examination more than five times in the past 14 years. We analyzed retrospectively the past liver function test results of these 63 subjects and evaluated their present virological status by determining HCV genotypes and estimating quantity of HCV RNA in the sera. Among the 63 subjects, 50 (79.4%) had HCV RNA in the serum and 40 (80%) of the 50 subjects with HCV RNA had abnormal alanine aminotransferase or aspartate aminotransferase level more than once in their records. However, the other 10 (20%) had no abnormal levels during the period examined. Six of 50 (12%) had ultrasonographic findings suggestive of cirrhosis. Thus, HCV-infected individuals in this area did not seem to have progressive liver diseases. Considering the advanced ages of the individuals examined (mean 64 years old), we may have observed a stage in the natural history of HCV infection in which viremia persists in most individuals and the tendency to progress to serious chronic liver disease is mild.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7851213     DOI: 10.1007/bf02065436

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; Y Gibo; K Yoshizawa; Y Nakano; S Furuta; Y Akahane; K Nishioka; R H Purcell
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

2.  Prevalence of antibody against non-A, non-B hepatitis virus in Japanese patients with hepatocellular carcinoma.

Authors:  S Ohkoshi; H Kojima; H Tawaraya; T Miyajima; T Kamimura; H Asakura; A Satoh; S Hirose; M Hijikata; N Kato
Journal:  Jpn J Cancer Res       Date:  1990 Jun-Jul

3.  The role of chronic viral hepatitis in hepatocellular carcinoma in the United States.

Authors:  A M Di Bisceglie; S E Order; J L Klein; J G Waggoner; M H Sjogren; G Kuo; M Houghton; Q L Choo; J H Hoofnagle
Journal:  Am J Gastroenterol       Date:  1991-03       Impact factor: 10.864

4.  Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease.

Authors:  G Dusheiko; H Schmilovitz-Weiss; D Brown; F McOmish; P L Yap; S Sherlock; N McIntyre; P Simmonds
Journal:  Hepatology       Date:  1994-01       Impact factor: 17.425

5.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

6.  Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group.

Authors:  L B Seeff; Z Buskell-Bales; E C Wright; S J Durako; H J Alter; F L Iber; F B Hollinger; G Gitnick; R G Knodell; R P Perrillo
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

7.  Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis.

Authors:  Y H Chung; Y K Shong
Journal:  Am J Gastroenterol       Date:  1993-02       Impact factor: 10.864

8.  Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis.

Authors:  G Realdi; A Alberti; M Rugge; A M Rigoli; F Tremolada; L Schivazappa; A Ruol
Journal:  Gut       Date:  1982-04       Impact factor: 23.059

9.  Cirrhosis: diagnosis with sonographic study of the liver surface.

Authors:  A Di Lelio; C Cestari; A Lomazzi; L Beretta
Journal:  Radiology       Date:  1989-08       Impact factor: 11.105

Review 10.  Antiviral therapy of hepatitis C--present and future.

Authors:  J H Hoofnagle; A M Di Bisceglie; M Shindo
Journal:  J Hepatol       Date:  1993       Impact factor: 25.083

View more
  4 in total

1.  Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients.

Authors:  Mitsuhiro Takimoto; Shogo Ohkoshi; Takafumi Ichida; Yasuo Takeda; Minoru Nomoto; Hitoshi Asakura; Akira Naito; Shigeki Mori; Kojiro Hata; Kentaro Igarashi; Hidenori Hara; Hironobu Ohta; Kenji Soga; Toshiaki Watanabe; Tomoteru Kamimura
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

2.  Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases.

Authors:  G Montalto; A L Zignego; M I Ruggeri; C Giannini; M Soresi; M Monti; A Carroccio; G Careccia; D Di Martino; F Giannelli
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

3.  Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan.

Authors:  Hirofumi Uto; Joji Kurogi; Yuka Takahama; Kazunori Kusumoto; Katsuhiro Hayashi; Akio Ido; Michinori Kohara; Sherri O Stuver; Akihiro Moriuchi; Susumu Hasegawa; Makoto Oketani; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2007-08-24       Impact factor: 7.527

4.  Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study.

Authors:  Hirofumi Uto; Sherri O Stuver; Katsuhiro Hayashi; Kotaro Kumagai; Fumisato Sasaki; Shuji Kanmura; Masatsugu Numata; Akihiro Moriuchi; Susumu Hasegawa; Makoto Oketani; Akio Ido; Kazunori Kusumoto; Satoru Hasuike; Kenji Nagata; Michinori Kohara; Hirohito Tsubouchi
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.